Clinical stage biopharmaceutical company Soligenix has received US patent for the vaccine thermostabilization technology, ThermoVax.
The patent claims describe methods of preparing an immunologically-active adjuvant-bound, thermostable, freeze dried vaccine composition that uses conventional adjuvants comprised of aluminum salts, in addition to claims covering the adjuvant-bound composition itself.
Soligenix president and chief executive officer Christopher Schaber said the issuance of patent for ThermoVax program is vital for commercialization strategy for vaccines to avoid increased costs and logistical burdens associated with cold chain storage and distribution.
"We expect that the introduction of an effective technology for long-term stabilization of vaccines has the potential to be a major advance in the national effort to develop effective countermeasures and therapies for significant biothreats and emerging pathogens," Schaber added.
ThermoVax was developed to avoid problems associated with freeze-drying vaccines that contain aluminum adjuvants at the same time engineering them to resist high temperatures.
The technology is exclusively licensed to Soligenix by the University of Colorado.
